Attovia Therapeutics (ATTO)
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Attovia Therapeutics Analyst Rating
View moreForecast & Rating
Sep 3, 2026Price forecast
$42.20118.20%
Forecast & RatingStrong buy
5analysts
- Strong buy60.00%
- Buy40.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Sep 9 at 12:14 PM
Attovia Therapeutics, Inc. (NASDAQ:ATTO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
- Market Beat · Sep 7 at 05:20 AM
Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End on September 14th
- rttnews · Sep 4 at 09:20 AM
Biotech Stocks At 52-Week Highs - ATTO, HALO, IKT, TVTX, ATRC
- Unusual Whales · Sep 3 at 08:07 PM
Attovia Therapeutics to Participate in Upcoming Investor Conferences
- rttnews · Sep 3 at 04:50 PM
Attovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27
